← All Altamira Therapeutics LTD filings

Altamira Therapeutics LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

CYTO
Altamira Therapeutics LTD
20-F: Altamira Therapeutics Repositions for RNA Delivery Focus, Reports Annual Results
Altamira Therapeutics shifts focus to RNA delivery technology, divesting legacy assets and reporting its financial results for the year ended December 31, 2024.
CYTO
Altamira Therapeutics LTD
20-F/A: Altamira Therapeutics Files Amendment No. 2 to 20-F, Including Audited Financials for Altamira Medica AG
Altamira Therapeutics files an amendment to its 2023 annual report to include the audited financial statements of Altamira Medica AG, as required by SEC regulations.
CYTO
Altamira Therapeutics LTD
20-F/A: Altamira Therapeutics Amends 20-F Filing to Correct Accounting Firm Report Date
Altamira Therapeutics files an amendment to its 20-F annual report solely to correct the date of the independent auditor's report and include certifications from the CEO and CFO.
CYTO
Altamira Therapeutics LTD
20-F: Altamira Therapeutics Repositions for RNA Delivery, Reports Annual Results in Form 20-F
Altamira Therapeutics focuses on RNA delivery technology, divesting non-core assets and reporting its annual results in a Form 20-F filing.